These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12552793)

  • 41. [Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats].
    Zhang YJ; Wang XL; Wu JM; Cheng MX
    Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):801-4. PubMed ID: 17639978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on drug-eluting coronary stents.
    Kipshidze NN; Tsapenko MV; Leon MB; Stone GW; Moses JW
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):953-68. PubMed ID: 16181039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous subacute stent thrombosis of two drug-eluting stents in the left anterior descending and the circumflex coronary arteries. Case report and review of the literature.
    Movahed MR; Vu J; Ahsan C
    J Invasive Cardiol; 2006 Jul; 18(7):E198-202. PubMed ID: 16816448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Percutaneous coronary intervention: historical perspectives, current status, and future directions.
    Arjomand H; Turi ZG; McCormick D; Goldberg S
    Am Heart J; 2003 Nov; 146(5):787-96. PubMed ID: 14597926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
    Kumbhani DJ; Bavry AA; Bhatt DL
    Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of stent design and coatings on restenosis and thrombosis.
    Hara H; Nakamura M; Palmaz JC; Schwartz RS
    Adv Drug Deliv Rev; 2006 Jun; 58(3):377-86. PubMed ID: 16650911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Local hirudin application--an aid in preventing occlusion of an arteriovenous fistula in dialysis patients?
    Minar E; Zazgornik J
    Klin Wochenschr; 1985 Feb; 63(4):190-1. PubMed ID: 3981957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronary brachytherapy in the drug-eluting stent era: don't bury it alive.
    Waksman R; Weinberger J
    Circulation; 2003 Jul; 108(4):386-8. PubMed ID: 12885731
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical and experimental studies on the effect of external drugs containing hirudin].
    Mittelstaedt R
    Arzneimittelforschung; 1973 Apr; 23(4):581-3. PubMed ID: 4740239
    [No Abstract]   [Full Text] [Related]  

  • 50. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.
    Grines CL; Bonow RO; Casey DE; Gardner TJ; Lockhart PB; Moliterno DJ; O'Gara P; Whitlow P; ; ; ; ; ;
    J Am Coll Cardiol; 2007 Feb; 49(6):734-9. PubMed ID: 17291948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.
    Grines CL; Bonow RO; Casey DE; Gardner TJ; Lockhart PB; Moliterno DJ; O'Gara P; Whitlow P; ; ; ; ; ;
    Circulation; 2007 Feb; 115(6):813-8. PubMed ID: 17224480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late thrombosis and drug-eluting stents.
    Williams D
    Med Device Technol; 2006; 17(9):8, 10. PubMed ID: 17240679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TCT Daily: safety profile of drug-eluting stents similar to bare-metal stents: lower restenosis rates associated with DES.
    Kahn J
    J Interv Cardiol; 2007 Feb; 20(1):30-1. PubMed ID: 17300395
    [No Abstract]   [Full Text] [Related]  

  • 54. Hirudin and its reversal.
    Dornan RI
    Br J Anaesth; 2002 Sep; 89(3):524; author reply 524. PubMed ID: 12402738
    [No Abstract]   [Full Text] [Related]  

  • 55. [Polymeric systems with antithrombin activity for thermally activated targeting].
    Valuev IL; Pan AV; Rozenfel'd MA; Valuev LI; Platé NA
    Prikl Biokhim Mikrobiol; 2003; 39(3):359-62. PubMed ID: 12754837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-eluting stents in peripheral vascular disease: eliminating restenosis.
    Ellozy SH; Carroccio A
    Mt Sinai J Med; 2003 Nov; 70(6):417-9. PubMed ID: 14647877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zotarolimus (ABT-578) eluting stents.
    Burke SE; Kuntz RE; Schwartz LB
    Adv Drug Deliv Rev; 2006 Jun; 58(3):437-46. PubMed ID: 16581153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Drug-eluting stents: long-term safety].
    Karpov IuA; Samko AN; Buza VV
    Ter Arkh; 2009; 81(5):36-41. PubMed ID: 19537584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacology and controlled release of hirudin for cardiovascular disorders.
    Kim DD; Horbett TA; Takeno MM; Ratner BD
    Cardiovasc Pathol; 1996; 5(6):337-49. PubMed ID: 25851791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.